The opioid misuse crisis continues to negatively impact the lives of patients while costing our health care system billions of dollars. This is why it still deserves our focus.

Join myMatrixx’s Phil Walls and The Hartford’s Adam Seidner as they explore alternative approaches to opioid pain management in workers’ compensation claims.

A CompTalk presented by the National Comp Conference dives into fentanyl’s transformation into one of the deadliest opioids in today’s epidemic.

A new report concluded that COVID-19 has led to increased opioid abuse, medical marijuana legislation and drugs delivered by mail.

Unaddressed behavioral health factors can drive up costs for payers and expose injured workers to delayed return-to-work and painkiller addiction.

Despite regulation meant to curb abuse of physician dispensing, it’s still a common practice and presents both safety and financial risks. 

The latest court filings and cases that will have an impact on the risk management and insurance industry.

The N.Y. DFS files charges against Teva Pharmaceuticals and Allergan for insurance fraud in connection to the state’s opioid crisis.

Two WCRI reports shed light on drug regulations and spend in workers’ comp.

While musculoskeletal disorders can be difficult to treat, one of the most effective tools against chronic pain can be found in our brains rather than in a prescription bottle. 

Musculoskeletal disorders can lead to opioid abuse, but workplace ergonomics can make a difference. Let’s not forget the urgency of the opioid epidemic in the wake of COVID-19.

A session at WCRI’s annual Issues & Research Conference will examine the mental health hurdles injured workers face.

As the opioid epidemic wears on, these employers are taking action to fight addiction in the workplace. Here are four ideas you can steal.

When refining a return-to-work program, employers can often overlook this one, crucial element: The interactions medications have on their injured workers.

A panel at the 2019 National Workers’ Compensation and Disability Conference® & Expo titled “The Opioid Epidemic: Mitigating Employee Safety and Health Risks” drew audience attention to alternatives that are helping curb the crisis.

Absenteeism, higher rates of accidents and frequent tardiness are making this already costly epidemic even more expensive.

From mounting opioid litigation to the more recent Risperdal suit, J&J is in the hot seat, teaching other companies the value reputation can hold.

The poisonous actions of pharma companies peddling painkillers are a social scourge that cannot be accepted.

High prescription drug costs are a huge issue in workers’ compensation, but there are a few ways to tackle the rising costs.

With more than 2,000 lawsuits pending across the country, drug manufacturer Johnson & Johnson is in the legal hot seat.